Overactive bladder is a chronic condition that affects 10–45% of women worldwide;1 however, more than half of women discontinue conservative and medical treatment.2,3 Predicting which women are better ...

FDA grants fast track designation to azer-cel, an allogeneic CAR T-cell therapy, for relapsed or refractory diffuse large ...

Sanofi has agreed to acquire DR-0201, a targeted bispecific myeloid cell engager, from Dren Bio Inc. for $600 million upfront ...

China’s National Medical Products Administration (NMPA) has granted conditional approval for Hutchmed’s Tazverik ...

Wojciech Jurczak, MD, PhD, ​​discusses nemtabrutinib and its development for the treatment of follicular lymphoma.

Data incorporated for this study were collected from 9 centers in the UK focused on third-line and beyond chimeric antigen ...

TAZVERIK ® is a registered trademark of Epizyme Inc., an Ipsen company.

Hutchmed (HCM) announces that the New Drug Application for Tazverik has been granted conditional approval in China for the treatment of adult ...

Lightweight refractory linings play an increasingly important role when it comes to achieving greater energy efficiency and ...

Received CIRM Grant funds for clinical development of SENTI-202: In January 2025, the Company also received an additional $1.5 million from its $8 million grant from the California Institute for ...

During a live event, Catherine J. Lee, MD, MS, discussed the efficacy and safety results of various trials of approved agents ...